ライフサイエンスコーパス: hyperfractionate

1 py with either total-body irradiation (TBI) (hyperfractionated 15 Gy)/melphalan (180 mg/m(2)) or thio

2 ence between the study treatment (continuous hyperfractionated accelerated radiotherapy [CHART]) and

3 CHART (continuous hyperfractionated accelerated radiotherapy) is the most

4 rvations, we developed the CHART (continuous hyperfractionated accelerated radiotherapy) regimen, whi

5 The efficacy of low RT doses of 32 Gy (hyperfractionated, accelerated RT [HART]) and 36 and 41.

6 of radiation (RT) in both standard daily and hyperfractionated-accelerated (HA) twice-daily RT schedu

7 nce-daily RT cohorts) or 1.5 Gy twice a day (hyperfractionated cohorts).

8 eived induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and mainten

9 to conventionally fractionated CRT (CFX) or hyperfractionated CRT (HFX) to a total dose of 18 Gy.

10 BP patients received hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, adriamy

11 to eight courses of the hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine, doxorub

12 Patients received eight cycles of hyperfractionated cyclophosphamide, vincristine, doxorub

13 ycles of intensive chemotherapy (hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorub

14 ients with Ph(+) ALL who received first-line hyperfractionated cyclophosphamide, vincristine, doxorub

15 st reported results have been with rituximab-hyperfractionated cyclophosphamide-vincristine-doxorubic

16 ard) or twice daily for 2 consecutive weeks (hyperfractionated) during a 21-day cycle.

17 platin chemotherapy (100 microg/delivery) or hyperfractionated external beam radiotherapy (EBRT; 15 G

18 of two chemotherapy arms administered before hyperfractionated external-beam radiotherapy (HFEBRT).

19 all survival benefit being restricted to the hyperfractionated group (HR 0.83, 0.74-0.92), with absol

20 is more efficacious and not more toxic than hyperfractionated irradiation alone.

21 otherapy (combined treatment) is superior to hyperfractionated irradiation alone.

22 We investigated whether hyperfractionated irradiation plus concurrent chemothera

23 d and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice dai

24 ped in three types of altered fractionation: hyperfractionated, moderately accelerated, and very acce

25 In lung cancer, randomized trials assessing hyperfractionated or accelerated radiotherapy seem to yi

26 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid

27 sophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.

28 e and tolerable concomitant chemotherapy and hyperfractionated radiation regimen that induces sustain

29 cell head and neck cancer were treated with hyperfractionated radiation therapy (72 Gy at 1.2 Gy twi

30 fluorouracil administration and accelerated, hyperfractionated radiation therapy.

31 ean age = 51.6 yrs) received conventional or hyperfractionated radiotherapy (63-76.8 Gy) for primary

32 aged and randomly assigned to treatment with hyperfractionated radiotherapy (HFRT) or standard (conve

33 mucositis, dysphagia, and xerostomia during hyperfractionated radiotherapy (n = 40) but not standard

34 The comparison between hyperfractionated radiotherapy and concomitant chemoradi

35 Split-course hyperfractionated radiotherapy did not increase the rate

36 benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment of local

37 low-up than the first version of MARCH, that hyperfractionated radiotherapy is, along with concomitan

38 ms to confirm and explain the superiority of hyperfractionated radiotherapy over other altered fracti

39 ompared with conventional radiotherapy, with hyperfractionated radiotherapy showing the greatest bene

40 In hyperfractionated radiotherapy the dose per fraction is

41 livered in daily 2-Gy fractions to 70 Gy, or hyperfractionated radiotherapy was delivered in 1.25-Gy

42 Hyperfractionated radiotherapy with concomitant chemothe

43 mide, and vincristine, and a split course of hyperfractionated radiotherapy.

44 a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignifi

45 Forty patients (30 standard and 10 hyperfractionated) received 533 injections of ONYX-015.

46 ain (47% on the standard regimen, 80% on the hyperfractionated regimen).

47 Gy/d), and the final three patients received hyperfractionated RT (76.8 Gy, 1.2 Gy bid).

48 zed to receive conventional RT (C-RT) versus hyperfractionated RT (HF-RT).

49 A greater difference was evident for hyperfractionated RT and platinum-based chemotherapy.

50 Concurrent chemoradiotherapy with hyperfractionated RT is feasible in this patient populat

51 Subset analysis of studies using hyperfractionated RT revealed OS RR for ERT versus LRT o

52 we added paclitaxel to the FHX base and used hyperfractionated RT to determine the maximum-tolerated

53 The addition of infusional paclitaxel and hyperfractionated RT to FHX is feasible.

54 s whether shortening treatment duration with hyperfractionated RT would be feasible and improve locor

55 matched allogeneic sibling transplants using hyperfractionated TBI and cyclophosphamide for patients

56 Radiation consisted of accelerated hyperfractionated thoracic radiation (AHTRT) 1.5 Gy bid

57 e (PIEo) given concurrently with accelerated hyperfractionated thoracic radiation was studied in pati

58 The cytoreductive regimen consisted of hyperfractionated total body irradiation (HFTBI), thiote

59 ied allogeneic HLA-matched sibling BMT after hyperfractionated total body irradiation (TBI) and cyclo

60 tive and graft-versus-host disease regimens (hyperfractionated total body irradiation, cyclophosphami

61 ed myeloablative cytoreduction consisting of hyperfractionated total body irradiation, thiotepa, and

62 Hyperfractionated treatment resulted in 10% complete res

63 a randomized clinical trial to test whether hyperfractionated (twice daily) cranial radiation therap

64 mozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and s